Browsing Tag
Inc.
232 posts
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more.
How CLR 125 may test the limits of precision radiopharmaceutical therapy in solid tumors
Could CLR 125 redefine precision radiopharmaceutical therapy in solid tumors? Read what this means for Cellectar Biosciences, Inc. and oncology markets.
Can Transglobal Management Group, Inc. turn Apache Creek into a scalable golf SaaS and marketplace model?
Can Transglobal Management Group, Inc. scale Apache Creek into a golf SaaS and marketplace platform? Read the full executive analysis on what comes next.
What this Phase 1 milestone reveals about the next wave of GPCR-driven endocrine therapeutics
What does Septerna’s Phase 1 milestone mean for GPCR-driven endocrine innovation? Read how SEP-479 could reshape biotech strategy and market sentiment.
Can Kyndryl (NYSE: KD) rebuild trust before its next earnings catalyst?
Kyndryl (NYSE: KD) faces a crucial earnings catalyst. Read what the selloff, AI push, and control issues mean for investors now.
Why High Roller Technologies’ Crypto.com deal could reshape its long-term revenue story
Find out why High Roller Technologies’ Crypto.com partnership could transform its long-term revenue model and reshape investor sentiment in prediction markets.
Is MiniMed (Nasdaq: MMED) worth watching after its IPO slide and before June earnings?
MiniMed (Nasdaq: MMED) is down from its IPO price. Read what June earnings, new product launches, and analyst targets could mean next.